This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, J. A. Search for Related Content PubMed PubMed Citation Articles by Johnson, J. A. Related Collections Congestive Cardiovascular Pharmacology Coagulation Clinical Studies Genetics of cardiovascular disease

(Circulation. 2008;118:1383-1393.)
© 2008 American Heart Association, Inc.

New Drugs and Technologies

Ethnic Differences in Cardiovascular Drug Response

Potential Contribution of Pharmacogenetics

Julie A. Johnson, PharmD

From the Departments of Pharmacy Practice, Pharmaceutics and Medicine, Center for Pharmacogenomics, University of Florida, Gainesville, Fla.

Correspondence to Julie A. Johnson, PharmD, Center for Pharmacogenomics, University of Florida, Box 100486, Gainesville, FL 32610-0486. E-mail johnson@cop.ufl.edu

Key Words: hypertension • heart failure • anticoagulants • pharmacogenetics • ethnicity

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
In the early 1980s, clinical differences in response to the blood pressure (BP)-lowering effects of β-blockers and, to a lesser extent, diuretics were noted between ethnic groups. The most convincing evidence at that time came from a Veterans Affairs (VA) Cooperative Trial,¹ which, along with other smaller studies, suggested that whites (those of European ancestry) had a better antihypertensive response to β-blockers than blacks (those of African ancestry), whereas blacks had a slight better response to diuretics than whites. Shortly after the first angiotensin-converting enzyme (ACE) inhibitor was approved in the mid-1980s, it was also recognized that whites responded more favorably to ACE inhibitors than did blacks. Over time, these differences in response became well accepted, such that ethnicity began to be used in helping to guide selection of antihypertensive drug therapy.^2,3 Although the ethnic differences in response between β-blockers and ACE inhibitors in hypertension are perhaps the mostly widely recognized examples of ethnic differences in response to cardiovascular drugs, there are others.

Pharmacogenetics is a field that seeks to unravel the genetic underpinnings of variable drug responses.⁴ Given the recognized ethnic differences in drug responses and the fact that many genetic polymorphisms differ in frequency on the basis of ethnicity/ancestry, questions about whether pharmacogenetics may also lead to an understanding of the ethnic differences in drug response are not surprising. The present review will summarize the most widely recognized examples of cardiovascular drugs with differential response by ethnicity and the evidence that pharmacogenetics data may aid in our understanding . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Bhopal Medicine and public health in a multiethnic world J. Public Health Med., September 1, 2009; 31(3): 315 - 321. [Abstract] [Full Text] [PDF]